ArticleFrontiers in cellular and infection microbiology2021
Combined Signature of the Urinary Microbiome and Metabolome in Patients With Interstitial Cystitis.
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- The urinary microbiome, overactive bladder and bladder pain syndrome/interstitial cystitis - mechanisms, diagnostics and therapeutic opportunities.Nature reviews. Urology · 2026Review
- Characterising the urinary metabolome in HIV/TB coinfection and the impact of antiretroviral treatment.BMC infectious diseases · 2026Article
- Characterization and comparative analysis of urinary bacterial microbiome profiling in healthy cats and cats with feline idiopathic cystitis.Scientific reports · 2026Article
- Multi-omics analysis identifies a microbiota-bile acid-TLR signaling axis driving bladder injury in interstitial cystitis.Nature communications · 2025Article
- The urinary microbiome: the next frontier of bacterial ecology.Journal of bacteriology · 2025Review
- Multi-omics profiling reveals distinct pathogenic mechanisms in Hunner and non-Hunner interstitial cystitis subtypes.Scientific reports · 2025Article
- Role of microbiota in pain: From bench to bedside.iMetaOmics · 2025Review
- SPHK1/S1PR1/PPAR-α axis restores TJs between uroepithelium providing new ideas for IC/BPS treatment.Life science alliance · 2025Article
- An Overview of the Association of the Urinary Tract Microbiome with Various Diseases and Implications for Therapeutics.Mini reviews in medicinal chemistry · 2025Review
- Exploring urinary microbiome: insights into neurogenic bladder and improving management of urinary tract infections.Frontiers in cellular and infection microbiology · 2025Review
- Dextrose Prolotherapy's Impact on the Urinary Microbiome in Interstitial Cystitis/Bladder Pain Syndrome.International journal of medical sciences · 2025Article
- The Response of the Urinary Microbiome to Botox.International urogynecology journal · 2024Article
- Urinary Microbiome in Bladder Diseases-Review.Biomedicines · 2023Review
- Integrated microbiome and metabolome analysis reveals novel urinary microenvironmental signatures in interstitial cystitis/bladder pain syndrome patients.Journal of translational medicine · 2023Article
- Microbiome in urological diseases: Axis crosstalk and bladder disorders.Investigative and clinical urology · 2023Review
- Cataloging variation in 16S rRNA gene sequences of female urobiome bacteria.Frontiers in urology · 2023Article
- Dysbiosis of the Human Urinary Microbiome and its Association to Diseases Affecting the Urinary System.Indian journal of microbiology · 2022Review
- Article
- Bladder Microbiome in the Context of Urological Disorders-Is There a Biomarker Potential for Interstitial Cystitis?Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial cystitis (IC) is a clinical syndrome characterized by frequency, urgency, and bladder pain or pelvic pain; however, the underlying pathophysiological mechanisms and diagnostic markers are unknown. In this study, microbiome and metabolome analysis were used to explain the urine signatures of IC patients. Urine samples from 20 IC patients and 22 control groups were analyzed by using 16S rRNA sequence and liquid chromatography coupled with mass spectrometry. Four opportunistic pathogen genera, including Serratia, Brevibacterium, Porphyromonas, and Citrobacter, were significantly upregulated in IC group. The altered metabolite signatures of the metabolome may be related to sphingosine metabolism, amino acid metabolism, and fatty acid biosynthesis. Meanwhile, the associations were observed between different metabolites and microbiomes of IC. The present study suggests that the combined signatures of IC in urine microbiome and metabolome may become its prospective diagnostic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.